This is the $64M question that will be on many people’s mind after seeing two SABCS headlines today:
“Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancerwith Lymph Node Involvement.”
“Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer.”
In order to answer the question fairly, there are plenty of critical points we can look at in order to address it.
That’s the topic of today’s post in a nutshell… and yes, we do come to a firm conclusion.